Closed Research Trials Medical Services are available at the following Riverside Medical Clinic locations:

 

Closed Research Trials

Riverside Medical Clinic’s Clinical Research Closed Research Trials are dedicated to our community with access to cutting-edge medical treatments. By working with pharmaceutical and biotechnology companies, we take part in the latest treatments being developed for the U.S. market.

We specialize in trials in the following areas:

AsthmaCOPDRheumatoid Arthritis
DiabetesCancerAllergic Rhinitis
Infectious DiseasesChronic PainSkin Disorders
Migraine Headaches& More…

Patient safety and welfare is our first priority. All Enrolling Research Trials conducted at our clinic are FDA monitored and overseen by an Institutional Review Board. Our dedicated team of physicians and staff work together to ensure patient safety and integrity of study data throughout the entire process.

Allergic Rhinitis

Stallergenes: A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis.

Rheumatoid Arthritis

R-Pharm: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 2 –

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

R-Pharm: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 3 –

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy

R-Pharm:  Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4 –

A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis.

ADHD

Shire: A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years with Attention-Deficit/Hyperactivity Disorder (ADHD).

ADHD

Shire: A Phase 3, Open-label, Multicenter, 12-Month, Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed with Attention-deficit/Hyperactivity Disorder.

Asthma

Pearl Therapeutics:  A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma.

Sjögrens

Bristol-Myers Squibb:  A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sjögrens Syndrome.

Infectious Disease

CEM-102 Pharmaceuticals, Inc. / “A Randomized, Double-blind, Multi-center Study To Evaluate the Safety and Efficacy of Oral Sodium Fusidate (CEM-102) Compared to Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure  Infections”.

Please contact the Clinical Research Department for Closed Research Trials to see if you qualify at (951) 321-6473

Be a part of the solution and begin your new treatment option with the medicine of tomorrow!